Year: 2013
Type: article
Study design: Observational Study
Abstract: BACKGROUND: We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers. METHODS: An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers. RESULTS: These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001). CONCLUSIONS: The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD.
Source: PLoS ONE
Authors: Frank Schraml, Kewei Chen, Napatkamon Ayutyanont, Roontiva Auttawut, Jessica B. S. Langbaum, Wendy Lee, Xiaofen Liu, Dan Bandy, Stephanie Q. Reeder, Gene E. Alexander, Richard J. Caselli, Adam S. Fleisher, Eric M. Reiman, the Alzheimer’s Disease Neuroimaging Initiative
Institutions: Creighton University, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Banner Alzheimer’s Institute, Arizona Alzheimer’s Consortium, Arizona State University, Translational Genomics Research Institute, University of Arizona, Mayo Clinic in Arizona, University of California San Diego
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W2070863291